BioMimetic Therapeutics to Report 2007 Third Quarter Financial Results on November 13
Franklin, Tenn. – November 8, 2007 - BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced that the Company plans to release its financial results for the three months and nine months ended September 30, 2007 on Tuesday, November 13, 2007, and will host a conference call and audio webcast at 4:30 ET the same day. Dr. Samuel E. Lynch, president and CEO, and members of the Company's management team will host the call to discuss the Company's third quarter financial results and product development programs and business activities.
A live webcast of the conference call will be available on the Investor Relations section of BioMimetic's website at www.biomimetics.com. The webcast will be archived for at least 30 days following the call.
The conference call may be accessed on November 13, 2007 by dialing toll free 800-299-7089 (passcode: 25755840). The international dial in number is 617-801-9714, and the same passcode applies. It is recommended that participants log on or dial in to the call approximately 10 minutes prior to the scheduled start time in order to register for the call.
About BioMimetic Therapeutics
BioMimetic Therapeutics, Inc. is developing and commercializing bio-active recombinant protein-device combination products for the healing of musculoskeletal injuries and disease, including orthopedic, periodontal, spine and sports injury applications. BioMimetic received marketing approval from the FDA for its first product, GEM 21S ®, as a grafting material for bone and periodontal regeneration following completion of human clinical trials, which demonstrated the safety and efficacy of its platform technology in this indication. Additionally, the Company has clinical trials ongoing with its product candidates GEM OS®1 and GEM OS®2 in multiple orthopedic bone healing indications including the treatment of foot and ankle fusions and the stimulation of healing of fractures of the arm. The Company's product and lead product candidates all combine recombinant protein therapeutics with tissue specific scaffolds to actively stimulate tissue healing and regeneration.
For further information, visit www.biomimetics.com or contact Kearstin Patterson, corporate communications, at 615-236-4419.
Back to Headlines |
